Benitec Biopharma Inc. Announces Proposed Public Offering

Rhea-AI Summary

Benitec Biopharma (NASDAQ: BNTC) announced a proposed underwritten public offering of common stock (or pre-funded warrants) and a concurrent registered direct offering with long-term investor Suvretta Capital. The company will grant underwriters a 30-day 15% overallotment option. The offerings are expected to close on November 7, 2025, subject to customary closing and market conditions. The SEC declared effective a Form S-3 registration on September 29, 2025. Leerink Partners, TD Cowen and Evercore ISI are bookrunning managers. A prospectus supplement will be filed with the SEC and offering materials will be available from the bookrunners and the SEC website.

Positive

• Concurrent registered direct financing with Suvretta Capital
• SEC Form S-3 declared effective on Sept 29, 2025
• Bookrunners named: Leerink, TD Cowen, Evercore ISI

Negative

• Potential share dilution from public offering and pre-funded warrants
• Offerings subject to market conditions; completion not guaranteed
• Underwriters have a 30-day 15% overallotment increasing potential issuance

HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and intends to conduct a concurrent registered direct offering of its common stock with long-term investor Suvretta Capital. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to a number of additional shares of its common stock equal to 15% of the total number of shares of common stock (and pre-funded warrants to purchase common stock in lieu thereof) sold in the underwritten offering, on the same terms and conditions. The offerings are expected to close on November 7, 2025, subject to customary closing conditions. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Leerink Partners, TD Cowen and Evercore ISI are acting as bookrunning managers for the proposed offering.

The Securities and Exchange Commission (“SEC”) declared effective a registration statement on Form S-3 relating to these securities on September 29, 2025. A prospectus supplement relating to these offerings will be filed with the SEC. The offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained, when available, from Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com. Investors may also obtain these documents at no cost by visiting the SEC’s website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Benitec Biopharma Inc.

Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD).

Cautionary Note Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to the completion, timing and size of the proposed public offering and the concurrent registered direct offering and Benitec’s expectations with respect to granting the underwriters a 30-day option to purchase additional shares. No assurance can be given that the offerings discussed above will be completed on the terms described, or at all, or that the proceeds of the offerings will be used as indicated. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Benitec’s filings with the SEC. Benitec’s filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Benitec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Benitec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor Relations Contacts: Irina Koffler
LifeSci Advisors, LLC
Phone: (917) 734-7387
Email: ikoffler@lifesciadvisors.com

Source: Benitec Biopharma Inc.

FAQ

What is Benitec Biopharma (BNTC) offering in November 2025?

An underwritten public offering of common stock (or pre-funded warrants) plus a concurrent registered direct offering with Suvretta Capital.

When is the Benitec (BNTC) offering expected to close?

The offerings are expected to close on November 7, 2025, subject to customary closing and market conditions.

How much additional stock can underwriters buy in the BNTC offering?

Underwriters may buy up to an additional amount equal to 15% of shares sold within a 30-day option period.

Has Benitec (BNTC) completed SEC registration for the offering?

Yes. The SEC declared effective Benitec's Form S-3 registration statement on September 29, 2025.

Who are the bookrunning managers for the Benitec (BNTC) offering?

Leerink Partners, TD Cowen and Evercore ISI are acting as bookrunning managers.

Where can investors obtain the Benitec (BNTC) prospectus supplement?

The prospectus supplement will be filed with the SEC and available from the bookrunners or the SEC website.